About Diakonos
Diakonos is a company based in Houston (United States) founded in 2022. Diakonos has raised $31.4 million across 2 funding rounds from investors including Baylor College of Medicine, Restem and Brain Tumor Investment Fund. Diakonos offers products and services including DOC1021. Diakonos operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Diakonos Oncology Corp.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.4 M (USD)
in 2 rounds
-
Latest Funding Round
$20 M (USD), Seed
Jun 01, 2025
-
Investors
Baylor College of Medicine
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diakonos
Diakonos offers a comprehensive portfolio of products and services, including DOC1021.
Vaccine that stimulates immune response against cancer by mimicking viral infections.
Funding Insights of Diakonos
Diakonos has successfully raised a total of $31.4M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $20 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diakonos
Diakonos has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Baylor College of Medicine, Restem and Brain Tumor Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Philanthropic capital is invested to advance brain tumor treatments.
|
Locked | Locked | Locked | |
|
Health science courses and degrees are offered to students.
|
Locked | Locked | Locked | |
|
Advances cell therapies for autoimmune conditions through proprietary platforms.
|
Locked | Locked | Locked |
Investor details for Diakonos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diakonos
Investment portfolio details for Diakonos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diakonos
Detailed financials for Diakonos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diakonos Comparisons
Peer comparison for Diakonos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diakonos
Diakonos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Diakonos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diakonos
Complete news archive for Diakonos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diakonos
Diakonos was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Diakonos is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Mike Wicks is the current CEO of Diakonos.
Diakonos is a funded company, having raised a total of $31.4M across 2 funding rounds to date.
Diakonos was founded in 2022 and is headquartered in Houston, United States. Operations focus on the oncology sector, where immunotherapeutics are developed for cancer treatment. Services include dendritic cell vaccines targeting glioblastoma, pancreatic cancer, and sarcoma; intratumoral injections for bone and head and neck cancers; and CAR T cell therapies for HER2-positive breast cancer and solid tumors.
Diakonos's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Diakonos offers DOC1021.
Diakonos has 3 investors. Key investors include Baylor College of Medicine, Restem, and Brain Tumor Investment Fund.